Concepedia

Robert L. Redner

RL

Statistics

Publications

40

Citations

3.9K

H-Index

22

Active since

1979

Affiliations

UPMC Hillman Cancer Center(Current)

University of Pittsburgh

University of Pittsburgh Medical Center

National Heart Lung and Blood Institute

Cornell University

Robert L. Redner is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and acute myeloid leukemia therapy.

ORCID

Publications per year

1979–2025

40

Publications

40

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

David J. Kuter, James B. Bussel, Roger M. Lyons et al. · The Lancet · 2008 · 862 citations

, , +6

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

Jianxiang Wang, Taizo Hoshino, Robert L. Redner et al. · Proceedings of the National Academy of Sciences · 1998 · 522 citations

, , +17

An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation.

J T Holt, Robert L. Redner, Arthur W. Nienhuis · Molecular and Cellular Biology · 1988 · 473 citations · Full text

, , +17

Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.

Jianxiang Wang, Yogen Saunthararajah, Robert L. Redner et al. · PubMed · 1999 · 197 citations

, , +17

Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Michael Boyiadzis, Mounzer Agha, Robert L. Redner et al. · Cytotherapy · 2017 · 179 citations

, , +17

1–5 of 40